Literature DB >> 28691416

The relationship between major depressive disorder and glucose parameters: A cross-sectional study in a Chinese population.

You-Fan Peng1, Shi-Mao Zhong1, Yu-Hua Qin1.   

Abstract

BACKGROUND: Depressive symptoms have been linked with insulin resistance in middle-aged and elderly populations. A strong relationship between peripheral insulin resistance and glucose homeostasis imbalance has been well established in previous studies. The role of serum fructosamine and fasting blood glucose (FBG) in elevating glucose homeostasis has been documented in the literature.
OBJECTIVES: The aim of the study was to examine the association of serum fructosamine and FBG with major depressive disorder (MDD).
MATERIAL AND METHODS: The study analyzed the clinical characteristics and biochemical parameters of 305 patients with MDD and 312 healthy individuals.
RESULTS: Serum concentrations of lipoprotein-cholesterol (HDL-C), total protein (TP) and creatinine (Cr) were found to be significantly different between the two groups. Serum fructosamine and fasting blood glucose (FBG) concentrations were high in patients with MDD compared with healthy individuals (2.3 ± 0.26 vs. 2.1 ± 0.27, p = 0.018; 4.7 ± 0.45 vs. 4.5 ± 0.45, p < 0.001). The levels of serum fructosamine and FBG were also significantly higher in patients with MDD when all participants were stratified by gender. Age was found to be positively correlated with FBG, serum fructosamine and Cr (r = 0.203, p < 0.001; r = 0.129, p = 0.025; r = 0.129, p = 0.024), and negatively correlated with TP (r = -0.114, p = 0.047) in patients with MDD. However, there were no correlations between age and FBG, serum fructosamine or Cr in the healthy controls. In a multivariate logistic regression analysis, increased serum fructosamine and FBG concentrations were positively associated with MDD independently of age and gender, after adjustment for age and potential confounding factors (OR = 6.313, CI95 %:2.953-13.393, p < 0.001; OR = 2.251, CI95 %: 1.464-3.462, p < 0.001).
CONCLUSIONS: The study results suggest that increased serum fructosamine and FBG concentrations are associated with depressive conditions, which may influence glucose metabolism and impair glucose homeostasis in patients with MDD.

Entities:  

Keywords:  fasting blood glucose; m DOI ajor depressive disorder; serum fructosamine

Mesh:

Substances:

Year:  2017        PMID: 28691416     DOI: 10.17219/acem/63023

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  5 in total

1.  Association of depressive disorder with biochemical and anthropometric indices in adult men and women.

Authors:  Bum Ju Lee
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

2.  Prevalence and predisposing factors of depressive symptoms in patients with stable coronary artery disease: a cross-sectional single-center study.

Authors:  Yeshun Wu; Bin Zhu; Zijun Chen; Jiahao Duan; Ailin Luo; Ling Yang; Chun Yang
Journal:  Aging (Albany NY)       Date:  2019-06-17       Impact factor: 5.682

Review 3.  The Problem of Malnutrition Associated with Major Depressive Disorder from a Sex-Gender Perspective.

Authors:  Cielo García-Montero; Miguel A Ortega; Miguel Angel Alvarez-Mon; Oscar Fraile-Martinez; Adoración Romero-Bazán; Guillermo Lahera; José Manuel Montes-Rodríguez; Rosa M Molina-Ruiz; Fernando Mora; Roberto Rodriguez-Jimenez; Javier Quintero; Melchor Álvarez-Mon
Journal:  Nutrients       Date:  2022-03-06       Impact factor: 5.717

4.  Bone mineral density and oxidative stress in adolescent girls with anorexia nervosa.

Authors:  Alžbeta Čagalová; Ľubica Tichá; Alexandra Gaál Kovalčíková; Katarína Šebeková; Ľudmila Podracká
Journal:  Eur J Pediatr       Date:  2021-07-22       Impact factor: 3.183

5.  Depressive symptoms and metabolic syndrome components among older Chinese adults.

Authors:  Jing-Hong Liu; Yu-Xi Qian; Qing-Hua Ma; Hong-Peng Sun; Yong Xu; Chen-Wei Pan
Journal:  Diabetol Metab Syndr       Date:  2020-02-18       Impact factor: 3.320

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.